|
1
|
Baumgart DC and Sandborn WJ: Crohn's
disease. Lancet. 380:1590–1605. 2012. View Article : Google Scholar
|
|
2
|
Cho JH and Brant SR: Recent insights into
the genetics of inflammatory bowel disease. Gastroenterology.
140:1704–1712. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perencevich M and Burakoff R: Use of
antibiotics in the treatment of inflammatory bowel disease. Inflamm
Bowel Dis. 12:651–664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sartor RB: Therapeutic manipulation of the
enteric microflora in inflammatory bowel diseases: antibiotics,
probiotics, and prebiotics. Gastroenterology. 126:1620–1633. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prantera C: What role do antibiotics have
in the treatment of IBD? Nat Clin Pract Gastroenterol Hepatol.
5:670–671. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dignass A, Van Assche G, Lindsay JO, et al
European Crohn's and Colitis Organisation (ECCO): The second
European evidence-based Consensus on the diagnosis and management
of Crohn's disease: Current management. J Crohns Colitis. 4:28–62.
2010. View Article : Google Scholar
|
|
7
|
Higgins JP, Altman DG, Gotzsche PC, et al
Cochrane Bias Methods Group; Cochrane Statistical Methods Group:
The Cochrane Collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343:d59282011. View Article : Google Scholar
|
|
8
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Egger M, Davey Smith G, Schneider M, et
al: Bias in meta-analysis detected by a simple, graphical test.
BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arnold GL, Beaves MR, Pryjdun VO and Mook
WJ: Preliminary study of ciprofloxacin in active Crohn's disease.
Inflamm Bowel Dis. 8:10–15. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dewint P, Hansen BE, Verhey E, et al:
Adalimumab combined with ciprofloxacin is superior to adalimumab
monotherapy in perianal fistula closure in Crohn's disease: a
randomised, double-blind, placebo controlled trial (ADAFI). Gut.
63:292–299. 2014.PubMed/NCBI
|
|
12
|
Steinhart AH, Feagan BG, Wong CJ, et al:
Combined budesonide and antibiotic therapy for active Crohn's
disease: a randomized controlled trial. Gastroenterology.
123:33–40. 2002. View Article : Google Scholar
|
|
13
|
Thia KT, Mahadevan U, Feagan BG, et al:
Ciprofloxacin or metronidazole for the treatment of perianal
fistulas in patients with Crohn's disease: a randomized,
double-blind, placebo-controlled pilot study. Inflamm Bowel Dis.
15:17–24. 2009. View Article : Google Scholar
|
|
14
|
West RL, van der Woude CJ, Hansen BE, et
al: Clinical and endosonographic effect of ciprofloxacin on the
treatment of perianal fistulae in Crohn's disease with infliximab:
a double-blind placebo-controlled study. Aliment Pharmacol Ther.
20:1329–1336. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hammer HF: Gut microbiota and inflammatory
bowel disease. Dig Dis. 29:550–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chassaing B and Darfeuille-Michaud A: The
commensal microbiota and enteropathogens in the pathogenesis of
inflammatory bowel diseases. Gastroenterology. 140:1720–1728. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Prantera C and Scribano ML: Antibiotics
and probiotics in inflammatory bowel disease: why, when, and how.
Curr Opin Gastroenterol. 25:329–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hooper DC and Wolfson JS: Fluoroquinolone
antimicrobial agents. N Engl J Med. 324:384–394. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sanders CC, Sanders WE Jr and Goering RV:
Overview of preclinical studies with ciprofloxacin. Am J Med.
82:2–11. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peppercorn MA: Is there a role for
antibiotics as primary therapy in Crohn's ileitis? J Clin
Gastroenterol. 17:235–237. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Prantera C, Berto E, Scribano ML and
Falasco G: Use of antibiotics in the treatment of active Crohn's
disease: experience with metronidazole and ciprofloxacin. Ital J
Gastroenterol Hepatol. 30:602–606. 1998.
|
|
22
|
Greenbloom SL, Steinhart AH and Greenberg
GR: Combination ciprofloxacin and metronidazole for active Crohn's
disease. Can J Gastroenterol. 12:53–56. 1998.
|
|
23
|
Ishikawa T, Okamura S, Oshimoto H,
Kobayashi R and Mori M: Metronidazole plus ciprofloxacin therapy
for active Crohn's disease. Intern Med. 42:318–321. 2003.
View Article : Google Scholar
|
|
24
|
Colombel JF, Lémann M, Cassagnou M, et al:
A controlled trial comparing ciprofloxacin with mesalazine for the
treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques
des Affections Inflammatoires Digestives (GETAID). Am J
Gastroenterol. 94:674–678. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prantera C, Zannoni F, Scribano ML, et al:
An antibiotic regimen for the treatment of active Crohn's disease:
a randomized, controlled clinical trial of metronidazole plus
ciprofloxacin. Am J Gastroenterol. 91:328–332. 1996.
|
|
26
|
Lapidus A, Bernell O, Hellers G and
Lofberg R: Clinical course of colorectal Crohn's disease: a 35-year
follow-up study of 507 patients. Gastroenterology. 114:1151–1160.
1998.
|
|
27
|
Schwartz DA, Pemberton JH and Sandborn WJ:
Diagnosis and treatment of perianal fistulas in Crohn disease. Ann
Intern Med. 135:906–918. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wolf J: Ciprofloxacin may be useful in
Crohn's disease. Gastroenterology. 98:(abstract). A2121990.
|
|
29
|
Uza N, Nakase H, Ueno S, et al: The effect
of medical treatment on patients with fistulizing Crohn's disease:
a retrospective study. Intern Med. 47:193–199. 2008. View Article : Google Scholar
|
|
30
|
Turunen U, Farkkila M, Valtonen V, et al:
Longterm outcome of ciprofloxacin treatment in severe perianal or
fistulous Crohn's disease. Gastroenterology. 104:(abstract).
A7931993.
|
